Download PDF
Semin Liver Dis 2003; 23: 003-012
DOI: 10.1055/s-2003-41629
Copyright © 2002 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

Diagnostic Testing in Hepatitis C Virus Infection: Viral Kinetics and Genomics

Jean-Michel Pawlotsky
  • Department of Virology, Henri Mondor Hospital, University of Paris XII, Créteil, France
Further Information

Publication History

Publication Date:
21 August 2003 (online)

    Permissions and Reprints

ABSTRACT

Virological tools play a major role in the diagnosis of hepatitis C virus (HCV) infection and in ongoing decision-making based on the patient's virological response to therapy. Virological tools used to assess viral kinetics and viral genomics can also be applied to clinical and translational research, especially in studies aimed at understanding the mechanisms underlying HCV treatment failure. Viral kinetics studies are based on quantification of HCV RNA at prescribed intervals during treatment and mathematical modeling of HCV RNA dynamics. These studies require sensitive and specific HCV RNA assays with an extended dynamic range of quantification. Viral genomics methods are useful to correlate viral kinetics with the intrinsic genomic characteristics of the HCV infecting strain. The interpretation of results utilizing various viral genomics tools is difficult, however, and must include predictive structural and functional genomic analyses. These approaches will be particularly useful in studying the mechanisms of HCV treatment failure with new HCV inhibitors currently under development.

KEYWORDS

Hepatitis C virus - HCV RNA quantification - viral kinetics - viral genomics - HCV resistance

REFERENCES

  • 1 Choo Q L, Kuo G, Weiner A J. et al . Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome.  Science . 1989;  244 359-362
    CrossrefPubMedGoogle Scholar
  • 2 Fried M W, Shiffman M L, Reddy K R. et al . Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.  N Engl J Med . 2002;  347 975-982
    CrossrefPubMedGoogle Scholar
  • 3 Hadziyannis S J, Cheinquer H, Morgan T. et al . Peginterferon alfa-2a (40 KD) (Pegasys) in combination with ribavirin (RBV): efficacy and safety results from a phase III, randomized, double-blind, multicentre study examining effect of duration of treatment and RBV dose.  J Hepatol . 2002;  36(Suppl 1) 3
    PubMedGoogle Scholar
  • 4 Manns M P, McHutchison J G, Gordon S C. et al . Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.  Lancet . 2001;  358 958-965
    CrossrefPubMedGoogle Scholar
  • 5 Simmonds P. Viral heterogeneity of the hepatitis C virus.  J Hepatol . 1999;  31(Suppl 1) 54-60
    CrossrefPubMedGoogle Scholar
  • 6 Soler M, Pellerin M, Malnou C E. et al . Quasispecies heterogeneity and constraints on the evolution of the 5' noncoding region of hepatitis C virus (HCV): relationship with HCV resistance to interferon-alpha therapy.  Virology . 2002;  298 160-173
    CrossrefPubMedGoogle Scholar
  • 7 Ross R S, Viazov S O, Holtzer C D. et al . Genotyping of hepatitis C virus isolates using CLIP sequencing.  J Clin Microbiol . 2000;  38 3581-3584
    PubMedGoogle Scholar
  • 8 Ansaldi F, Torre F, Bruzzone B M. et al . Evaluation of a new hepatitis C virus sequencing assay as a routine method for genotyping.  J Med Virol . 2001;  63 17-21
    CrossrefPubMedGoogle Scholar
  • 9 Stuyver L, Rossau R, Wyseur A. et al . Typing of hepatitis C virus isolates and characterization of new subtypes using a line probe assay.  J Gen Virol . 1993;  74 1093-1102
    PubMedGoogle Scholar
  • 10 Stuyver L, Wyseur A, van Arnhem W. et al . Hepatitis C virus genotyping by means of 5′-UR/core line probe assays and molecular analysis of untypeable samples.  Virus Res . 1995;  38 137-157
    CrossrefPubMedGoogle Scholar
  • 11 Stuyver L, Wyseur A, van Arnhem W. et al . Second-generation line probe assay for hepatitis C virus genotyping.  J Clin Microbiol . 1996;  34 2259-2266
    PubMedGoogle Scholar
  • 12 Pawlotsky J M, Prescott L, Simmonds P. et al . Serological determination of hepatitis C virus genotype: comparison with a standardized genotyping assay.  J Clin Microbiol . 1997;  35 1734-1739
    PubMedGoogle Scholar
  • 13 Leruez-Ville M, Nguyen Q T, Cohen P. et al . Large-scale analysis of hepatitis C virus serological typing assay: effectiveness and limits.  J Med Virol . 1998;  55 18-23
    CrossrefPubMedGoogle Scholar
  • 14 Prescott L E, Berger A, Pawlotsky J M. et al . Sequence analysis of hepatitis C virus variants producing discrepant results with two different genotyping assays.  J Med Virol . 1997;  53 237-244
    CrossrefPubMedGoogle Scholar
  • 15 Sandres K, Dubois M, Pasquier C. et al . Determination of HCV genotype using two antibody assays and genome typing.  Eur J Clin Microbiol Infect Dis . 2001;  20 666-669
    CrossrefPubMedGoogle Scholar
  • 16 Neumann A U, Lam N P, Dahari H. et al . Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy.  Science . 1998;  282 103-107
    CrossrefPubMedGoogle Scholar
  • 17 Bouvier-Alias M, Patel K, Dahari H. et al . Clinical utility of total hepatitis C virus (HCV) core antigen quantification, a new indirect marker of HCV replication.  Hepatology . 2002;  36 211-218
    CrossrefPubMedGoogle Scholar
  • 18 Pawlotsky J M. Use and interpretation of virological tests for hepatitis C.  Hepatology . 2002;  36 S65-S73
    CrossrefPubMedGoogle Scholar
  • 19 Consensus conference. Treatment of hepatitis C.  Gastroenterol Clin Biol . 2002;  26 B303-B320
    PubMedGoogle Scholar
  • 20 National Institutes of Health Consensus Development Conference Statement. Management of hepatitis C 2002 (June 10-12, 2002).  Gastroenterology . 2002;  123 2082-2099
    CrossrefPubMedGoogle Scholar
  • 21 Hofer H, Watkins-Riedel T, Janata O. et al . Spontaneous viral clearance in patients with acute hepatitis C can be predicted by repeated measurements of serum viral load.  Hepatology . 2003;  37 60-64
    CrossrefPubMedGoogle Scholar
  • 22 Zeuzem S, Herrmann E, Lee J H. et al . Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon alpha2a.  Gastroenterology . 2001;  120 1438-1447
    PubMedGoogle Scholar
  • 23 Lam N P, Neumann A U, Gretch D R. et al . Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa.  Hepatology . 1997;  26 226-231
    PubMedGoogle Scholar
  • 24 Neumann A U, Lam N P, Dahari H. et al . Differences in viral dynamics between genotypes 1 and 2 of hepatitis C virus.  J Infect Dis . 2000;  182 28-35
    CrossrefPubMedGoogle Scholar
  • 25 Neumann A U, Buti M, Lurie Y. et al . The second phase HCV decline slope is the best predictor of sustained viral response during treatment of chronic HCV genotype 1 patients with peginterferon alfa-2b and ribavirin.  Hepatology . 2002;  36 357A
    PubMedGoogle Scholar
  • 26 Neumann A U, Zeuzem S, Ferrari C. et al . Ditto-HCV early viral kinetics report: novel decline patterns in genotype 1 but not genotypes 2 and 3 patients treated with peg-interferon alfa-2a and ribavirin.  J Hepatol . 2002;  36(Suppl 1) 121
    PubMedGoogle Scholar
  • 27 Pawlotsky J M, Neumann A U, Dahari H. et al . Hepatitis C virus dynamics during induction therapy with interferon alpha and/or ribavirin.  Hepatology . 2000;  32 223A
    PubMedGoogle Scholar
  • 28 Pawlotsky J M. Molecular diagnosis of viral hepatitis.  Gastroenterology . 2002;  122 1554-1568
    PubMedGoogle Scholar
  • 29 Urdea M S, Horn T, Fultz T J. et al . Branched DNA amplification multimers for the sensitive, direct detection of human hepatitis viruses.  Nucleic Acids Symp Ser . 1991;  24 197-200
    PubMedGoogle Scholar
  • 30 Saiki R K, Bugawan T L, Horn G T. et al . Analysis of enzymatically amplified beta-globin and HLA-DQ alpha DNA with allele-specific oligonucleotide probes.  Nature . 1986;  324 163-166
    CrossrefPubMedGoogle Scholar
  • 31 Compton J. Nucleic acid sequence-based amplification.  Nature . 1991;  350 91-92
    CrossrefPubMedGoogle Scholar
  • 32 Higuchi R, Fockler C, Dollinger G. et al . Kinetic PCR analysis: real-time monitoring of DNA amplification reactions.  Biotechnology (NY) . 1993;  11 1026-1030
    PubMedGoogle Scholar
  • 33 Heid C A, Stevens J, Livak K J. et al . Real time quantitative PCR.  Genome Res . 1996;  6 986-994
    PubMedGoogle Scholar
  • 34 Chen R W, Piiparinen H, Seppanen M. et al . Real-time PCR for detection and quantitation of hepatitis B virus DNA.  J Med Virol . 2001;  65 250-256
    CrossrefPubMedGoogle Scholar
  • 35 Andrus A, Cox S, Beavers S. et al . High-throughput synthesis of functionalized oligonucleotides.  Nucleic Acids Symp Ser . 1997;  317-318
    PubMedGoogle Scholar
  • 36 Parks S B, Popovich B W, Press R D. Real-time polymerase chain reaction with fluorescent hybridization probes for the detection of prevalent mutations causing common thrombophilic and iron overload phenotypes.  Am J Clin Pathol . 2001;  115 439-447
    CrossrefPubMedGoogle Scholar
  • 37 White P A, Pan Y, Freeman A J. et al . Quantification of hepatitis C virus in human liver and serum samples by using LightCycler reverse transcriptase PCR.  J Clin Microbiol . 2002;  40 4346-4348
    CrossrefPubMedGoogle Scholar
  • 38 Komurian-Pradel F, Paranhos-Baccala G, Sodoyer M. et al . Quantitation of HCV RNA using real-time PCR and fluorimetry.  J Virol Methods . 2001;  95 111-119
    CrossrefPubMedGoogle Scholar
  • 39 Yang J H, Lai J P, Douglas S D. et al . Real-time RT-PCR for quantitation of hepatitis C virus RNA.  J Virol Methods . 2002;  102 119-128
    CrossrefPubMedGoogle Scholar
  • 40 Takeuchi T, Katsume A, Tanaka T. et al . Real-time detection system for quantification of hepatitis C virus genome.  Gastroenterology . 1999;  116 636-642
    PubMedGoogle Scholar
  • 41 Martell M, Gomez J, Esteban J I. et al . High-throughput real-time reverse transcription-PCR quantitation of hepatitis C virus RNA.  J Clin Microbiol . 1999;  37 327-332
    PubMedGoogle Scholar
  • 42 Enomoto M, Nishiguchi S, Shiomi S. et al . Comparison of real-time quantitative polymerase chain reaction with three other assays for quantitation of hepatitis C virus.  J Gastroenterol Hepatol . 2001;  16 904-909
    CrossrefPubMedGoogle Scholar
  • 43 Lee C L, Schlag P, Antony A. et al . Evaluation of TaqMan HCV ASR.  Hepatology . 2002;  36 346A
    PubMedGoogle Scholar
  • 44 Saldanha J, Lelie N, Heath A. Establishment of the first international standard for nucleic acid amplification technology (NAT) assays for HCV RNA.  Vox Sang . 1999;  76 149-158
    CrossrefPubMedGoogle Scholar
  • 45 Saldanha J, Heath A, Lelie N. et al . Calibration of HCV working reagents for NAT assays against the HCV international standard.  Vox Sang . 2000;  78 217-224
    CrossrefPubMedGoogle Scholar
  • 46 Pawlotsky J M, Bouvier-Alias M, Hezode C. et al . Standardization of hepatitis C virus RNA quantification.  Hepatology . 2000;  32 654-659
    CrossrefPubMedGoogle Scholar
  • 47 Chazouilleres O, Kim M, Combs C. et al . Quantitation of hepatitis C virus RNA in liver transplant recipients.  Gastroenterology . 1994;  106 994-999
    PubMedGoogle Scholar
  • 48 Duvoux C, Pawlotsky J M, Bastie A. et al . Low HCV replication levels in end-stage hepatitis C virus-related liver disease.  J Hepatol . 1999;  31 593-597
    CrossrefPubMedGoogle Scholar
  • 49 Sulkowski M S, Thomas D L. Hepatitis C in the HIV-infected person.  Ann Intern Med . 2003;  138 197-207
    PubMedGoogle Scholar
  • 50 Thomas D L. Hepatitis C and human immunodeficiency virus infection.  Hepatology . 2002;  36 S201-S209
    CrossrefPubMedGoogle Scholar
  • 51 Pawlotsky J M, Martinot-Peignoux M, Poveda J D. et al . Quantification of hepatitis C virus RNA in serum by branched DNA-based signal amplification assays.  J Virol Methods . 1999;  79 227-235
    CrossrefPubMedGoogle Scholar
  • 52 Yu M L, Chuang W L, Dai C Y. et al . Clinical evaluation of the automated Cobas Amplicor HCV Monitor test version 2.0 for quantifying serum hepatitis C virus RNA and comparison to the Quantiplex HCV version 2.0 test.  J Clin Microbiol . 2000;  38 2933-2939
    PubMedGoogle Scholar
  • 53 Gerken G, Rothaar T, Rumi M G. et al . Performance of the Cobas Amplicor HCV Monitor test, version 2.0, an automated reverse transcription-PCR quantitative system for hepatitis C virus load determination.  J Clin Microbiol . 2000;  38 2210-2214
    PubMedGoogle Scholar
  • 54 Martinot-Peignoux M, Boyer N, Le Breton V. et al . A new step toward standardization of serum hepatitis C virus RNA quantification in patients with chronic hepatitis C.  Hepatology . 2000;  31 726-729
    CrossrefPubMedGoogle Scholar
  • 55 Lee S C, Antony A, Lee N. et al . Improved version 2.0 qualitative and quantitative Amplicor reverse transcription-PCR tests for hepatitis C virus RNA: calibration to international units, enhanced genotype reactivity, and performance characteristics.  J Clin Microbiol . 2000;  38 4171-4179
    PubMedGoogle Scholar
  • 56 Pawlotsky J M. Measuring hepatitis C viremia in clinical samples: can we trust the assays?.  Hepatology . 1997;  26 1-4
    PubMedGoogle Scholar
  • 57 Pradat P, Chossegros P, Bailly F. et al . Comparison between three quantitative assays in patients with chronic hepatitis C and their relevance in the prediction of response to therapy.  J Viral Hepat . 2000;  7 203-210
    CrossrefPubMedGoogle Scholar
  • 58 Reichard O, Norkrans G, Fryden A. et al . Comparison of 3 quantitative HCV RNA assays. Accuracy of baseline viral load to predict treatment outcome in chronic hepatitis C.  Scand J Infect Dis . 1998;  30 441-446
    PubMedGoogle Scholar
  • 59 Weiner A J, Brauer M J, Rosenblatt J. et al . Variable and hypervariable domains are found in the regions of HCV corresponding to the flavivirus envelope and NS1 proteins and the pestivirus envelope glycoproteins.  Virology . 1991;  180 842-848
    CrossrefPubMedGoogle Scholar
  • 60 Martell M, Esteban J I, Quer J. et al . Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: quasispecies nature of HCV genome distribution.  J Virol . 1992;  66 3225-3229
    PubMedGoogle Scholar
  • 61 Pawlotsky J M, Germanidis G, Neumann A U. et al . Interferon resistance of hepatitis C virus genotype 1b: relationship to nonstructural 5A gene quasispecies mutations.  J Virol . 1998;  72 2795-2805
    PubMedGoogle Scholar
  • 62 Pawlotsky J M, Germanidis G, Frainais P O. et al . Evolution of the hepatitis C virus second envelope protein hypervariable region in chronically infected patients receiving alpha interferon therapy.  J Virol . 1999;  73 6490-6499
    PubMedGoogle Scholar
  • 63 Gretch D R, Polyak S J, Wilson J J. et al . Tracking hepatitis C virus quasispecies major and minor variants in symptomatic and asymptomatic liver transplant recipients.  J Virol . 1996;  70 7622-7631
    PubMedGoogle Scholar
  • 64 Polyak S J, McArdle S, Liu S L. et al . Evolution of hepatitis C virus quasispecies in hypervariable region 1 and the putative interferon sensitivity-determining region during interferon therapy and natural infection.  J Virol . 1998;  72 4288-4296
    PubMedGoogle Scholar
  • 65 Smith D B, McAllister J, Casino C. et al . Virus "quasispecies": making a mountain out of a molehill?.  J Gen Virol . 1997;  78 1511-1519
    PubMedGoogle Scholar
  • 66 Pawlotsky J M, Gretch D R. Molecular tools for the treatment of hepatitis C.  Antivir Ther . 1998;  3 45-55
    PubMedGoogle Scholar
  • 67 Pawlotsky J M. Antiviral treatment failure in chronic hepatitis C (in press).  Antiviral Res. 2003; 
    PubMedGoogle Scholar
  • 68 Penin F, Dubuisson J, Rey F. et al . Structural biology of hepatitis C virus (in press).  Hepatology . 2003; 
    PubMedGoogle Scholar
  • 69 McHutchison J G, Patel K. Future therapy of hepatitis C.  Hepatology . 2002;  36 S245-S252
    CrossrefPubMedGoogle Scholar
  • 70 Benhamou Y, Hinrichsen H, Sentjens R. et al . Safety, tolerability and antiviral effect of BILN 2061, a novel HCV serine protease inhibitor, after oral treatment over two days in patients with chronic hepatitis C, genotype 1, with advanced liver fibrosis.  Hepatology . 2002;  36 304A
    PubMedGoogle Scholar
  • 71 Hinrichsen H, Benhamou Y, Reiser M. et al . First report on the antiviral efficacy of BILN 2061, a novel oral serine protease inhibitor, in patients with chronic hepatitis C genotype 1.  Hepatology . 2002;  36 379A
    PubMedGoogle Scholar
  • 72 De Francesco R, Rice C M. New therapies on the horizon for hepatitis C: are we close ?.  Clin Liver Dis . 2003;  7 211-242
    CrossrefPubMedGoogle Scholar
  • 73 Soler M, Penin F, Ray S. et al . Hepatitis C virus NS3 serine protease variability and evolution are strongly constrained by the need for structural and functional conservation.  J Hepatol . 2002;  36(Suppl 1) 5
    PubMedGoogle Scholar
  • 74 Pietschmann T, Bartenschlager R. Tissue culture and animal models for hepatitis C virus.  Clin Liver Dis . 2003;  7 23-43
    PubMedGoogle Scholar
      >